BioWorld Asia

Jan. 6, 2010

F-star Gets $11.5M to Bolster Antibody Engineering Platform

F-star Biotechnologische Forschungs-und Entwicklungsges mbH added another €8 million (US$11.5 million) in a third closing of a Series A round that had previously yielded €9 million, spread across two tranches. (BioWorld International) Read More

Proximagen Buying Minister; Tonabersat Getting New Life

Map of Breast Cancer Genomes' Varied Landscape is Planned

Summit Pulls in £5.4M Funding, Becomes an Iminosugars Firm

Ireland Bioethics Council Funding Stopped as Legal Clouds Emerge

'Reddy' for Another PPAR Drug? Balaglitazone Solid in Phase III

Data Monitoring Deficiencies Sink Ceftobiprole Once Again

Compugen Nets $19M for Drug, Diagnostic Discovery Work

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Jan 16, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 16, 2026.

SERPINB1 as potential biomarker for spinocerebellar ataxia type 2

BioWorld Science

Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...

Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal

BioWorld

With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...

Illustration of human body surrounded by DNA, cell and drug icons

Cell/gene therapy sector now sustainable; China competition mounting

BioWorld

There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...